目的:研究銀杏達莫對糖尿病大鼠腎功能的影響,并從抗氧化應激反應的角度探討其可能的作用機制。方法:50只Wistar大鼠隨機分為正常組(10只),糖尿病模型組(20只)及糖尿病模型加銀杏達莫組(20只)。采用單次腹腔注射鏈脲佐菌素(55 mg/kg)誘導糖尿病腎病(DN)大鼠模型,腹腔注射銀杏達莫水溶液。生化法測定血糖,血、尿肌酐及尿白蛋白;尾靜脈取血ELISA法檢測血清血管內皮先長因子(VEGF)水平;腎臟勻漿后測腎臟丙二醛(MDA)、一氧化氮(NO)的含量。結果:糖尿病模型組和銀杏達莫組生化指標均高于正常組(P lt;0.05),銀杏達莫組MDA、NO及VEGF的表達減少與模型組比較差異有顯著性(P lt;0.05)。結論:銀杏達莫具有減輕糖尿病大鼠蛋白尿,提高尿肌酐排泄,減輕腎臟損害的作用,其機制可能與提高腎臟抗氧化系統功能有關。
引用本文:
楊廷強,張燕,沈成義. 腹腔注射銀杏達莫對糖尿病大鼠氧化應激及腎作用的研究. 華西醫學, 2009, 24(1): 132-134. doi:
復制
1. |
Koga K,Yamagishi S,Takeuchi M,et al.CS886,a new angiotensin Ⅱ type Ⅰ receptor antagonist,ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka LongEvans Tokushina fatty rats[J].Mol Med,2002,8(10):591-599.[7]Zeng L,Xu H,Chew TL,et al.HMG CoA reductase inhibition modulates VEGFinduced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation[J].FASEB J,2005,19(13):1845-1847.
|
- 1. Koga K,Yamagishi S,Takeuchi M,et al.CS886,a new angiotensin Ⅱ type Ⅰ receptor antagonist,ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka LongEvans Tokushina fatty rats[J].Mol Med,2002,8(10):591-599.[7]Zeng L,Xu H,Chew TL,et al.HMG CoA reductase inhibition modulates VEGFinduced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation[J].FASEB J,2005,19(13):1845-1847.